SAB Biotherapeutics (SABS) Earnings Date & Reports

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

SABS is expected to report earnings to fall 16.67% to -83 cents per share on March 28

SAB Biotherapeutics SABS Stock Earnings Reports

Q4'23

Est.

$-0.83

Q3'23

Missed

by $0.88

Q2'23

Missed

by $1.26

Q1'23

Missed

by $1.39

Q4'22

Missed

by $1.71

The last earnings report on November 14 showed earnings per share of -100 cents, missing the estimate of -11 cents. With 91.66K shares outstanding, the current market capitalization sits at 14.77M.

View a ticker or compare two or three

Compare

SABS